[The effect of recombinant interleukin-2 on the course of experimental staphylococcal peritonitis in mice].
The effect of RIL-2 on the survival of mice with S. aureus--induced peritonitis was studied. Animals received bacterial suspension and RIL-2 as following: bacteria--on days 0, +2, RIL-2--day 0 (group 1); bacteria--days 0, +4, RIL-2--days 0, +2 (group 2); bacteria--days 0, +6, RIL-2--days 0, +2, +4 (group 3). RIL-2 exerted no protective effect in group 1. However, in groups 2 and 3, where the control animals survival was, resp., 56% and 38%, the RIL-2 treatment increased survival up to, resp., 84% and 70%. Antibiotics given instead of RIL-2 in analogous regimen decreased the survival in group 3 to the level of 25%. Thus, RIL-2 proved to be a potent therapeutic agent in the 2nd of 3d studied models of S. aureus--induced peritonitis in mice. The perspectives of RIL-2 use in the treatment of bacterial peritonitis, including porous ones, and of the immunodepression--aggravated conditions are discussed.
Shadrin
O V
OV
Khar'kovskaia
N A
NA
Kaufman
O Ia
OIa
Tolcheev
Iu D
IuD
Dronova
O M
OM
Malakhova
N V
NV
Bykovskaia
S N
SN
D000818:Animals; D004195:Disease Models, Animal; D004353:Drug Evaluation, Preclinical; D005260:Female; D005839:Gentamicins / Q000627:therapeutic use; D007376:Interleukin-2 / Q000627:therapeutic use*; D051379:Mice; D010406:Penicillins / Q000627:therapeutic use; D010538:Peritonitis / Q000097:blood / Q000382:microbiology / Q000628:therapy*; D011994:Recombinant Proteins / Q000627:therapeutic use; D013203:Staphylococcal Infections / Q000097:blood / Q000382:microbiology / Q000628:therapy*; D013211:Staphylococcus aureus / Q000302:isolation & purification; D013307:Streptomycin / Q000627:therapeutic use; D013997:Time Factors
D005839:Gentamicins; D007376:Interleukin-2; D010406:Penicillins; D011994:Recombinant Proteins; D013307:Streptomycin
Vliianie rekombinantnogo interleĭkina-2 na techenie éksperimental'nogo stafilokokkovogo peritonita u mysheĭ.